Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Multiple organ failure

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    122 result(s) found for: Multiple organ failure. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2012-005159-18 Sponsor Protocol Number: CRO2047 Start Date*: 2013-08-28
    Sponsor Name:Imperial College, London
    Full Title: An efficacy and mechanism evaluation study of Levosimendan for the Prevention of Acute oRgan Dysfunction in Sepsis (LeoPARDS)
    Medical condition: Septic shock.
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004867 10028237 Multiple organ failure LLT
    16.0 10021881 - Infections and infestations 10040070 Septic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-002547-94 Sponsor Protocol Number: 2011-420 Start Date*: 2013-03-25
    Sponsor Name:Dept. of Intensive Care 4131, Rigshospitalet
    Full Title: Early Goal-Directed Nutrition in ICU Patients – EAT-ICU Trial
    Medical condition: Acutely admitted, mechanically ventilated intensive care unit patients.
    Disease: Version SOC Term Classification Code Term Level
    15.1 10038738 - Respiratory, thoracic and mediastinal disorders 10038738 Respiratory, thoracic and mediastinal disorders SOC
    15.1 100000004867 10028151 Multi organ failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-004856-35 Sponsor Protocol Number: DHTCA_P09889 Start Date*: 2008-03-17
    Sponsor Name:Imperial College London
    Full Title: Scavenging free haemoglobin atenuates the systemic inflmmatory response following surgery
    Medical condition: Systemic inflammatory response and associated multiorgan failure that follows cardiopulmonary bypass for cardiac surgery
    Disease: Version SOC Term Classification Code Term Level
    9.1 10062357 SIRS LLT
    9.1 10066123 Cardiopulmonary bypass LLT
    9.1 10018910 Haemolysis LLT
    9.1 10027803 MOF LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-002255-10 Sponsor Protocol Number: IRMINEpilot Start Date*: 2016-06-30
    Sponsor Name:Abertawe Bro Morgannwg University Health Board
    Full Title: INFLAMMATORY RESPONSE IN MAJOR INJURY & RECOMBINANT HUMAN ERYTHROPOIETIN (IRMINE) - A PILOT STUDY
    Medical condition: Post-trauma multiple organ failure: a manifestation of the systemic inflammatory/immune response to major injuries.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10021459 Immunodeficiency secondary to trauma LLT
    20.0 100000004867 10028237 Multiple organ failure LLT
    20.0 10022117 - Injury, poisoning and procedural complications 10044461 Trauma LLT
    20.0 10022117 - Injury, poisoning and procedural complications 10044541 Traumatic shock PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-000899-25 Sponsor Protocol Number: FP1CLI006 Start Date*: 2016-12-16
    Sponsor Name:Faron Pharmaceuticals Ltd
    Full Title: A Phase II Double-blind, Randomised, Parallel Group 2:1 Comparison of the Efficacy and Safety of FP-1201-lyo (Recombinant Human Interferon Beta-1a) and Placebo in the Prevention of Multi-Organ Fail...
    Medical condition: Prevention of Multi-Organ Failure on Patients Surviving Open Surgery for a Ruptured Abdominal Aortic Aneurysm.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004867 10028154 Multi-organ failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) EE (Prematurely Ended) LT (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-004886-33 Sponsor Protocol Number: A06-269 Start Date*: 2007-06-05
    Sponsor Name:University of Athens, Medical school
    Full Title: A DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED CLINICAL TRIAL OF THE SAFETY AND IMMUNOMODULATORY THERAPY FOR THE MANAGEMENT OF SEPSIS
    Medical condition: septic syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-021557-40 Sponsor Protocol Number: MM-Rel Start Date*: 2011-03-03
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: A phase III trial comparing bortezomib, cyclophosphamide and dexamethasone versus lenalinomide cyclophosphamide and dexamethasone in patients with multiple myeloma at first relapse
    Medical condition: Multiple mieloma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-004884-29 Sponsor Protocol Number: 12-BI-505-02 Start Date*: 2013-01-16
    Sponsor Name:BioInvent International AB
    Full Title: A single-arm, Open-label, Phase 2 Clinical Trial Evaluating Disease Response Following Treatment With BI-505, a Human Anti–Intercellular Adhesion Molecule 1 Monoclonal Antibody, In Patients With Sm...
    Medical condition: Smoldering (asymptomatic) multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-016871-32 Sponsor Protocol Number: 0911001 Start Date*: 2010-06-28
    Sponsor Name:CHU de TOULOUSE
    Full Title: A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplan...
    Medical condition: Myeloma, Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    12.0 10028228 Multiple myeloma LLT
    12.0 10028566 Myeloma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001594-31 Sponsor Protocol Number: 2022_0174 Start Date*: 2022-08-30
    Sponsor Name:CHU de LILLE
    Full Title: A Phase 2 Study of Teclistamab in Combination with Daratumumab or Lenalidomide in Elderly Patients with Newly Diagnosed Multiple Myeloma
    Medical condition: A Phase 2 Study of Teclistamab in Combination with Daratumumab or Lenalidomide in Elderly Patients with Newly Diagnosed Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-000301-40 Sponsor Protocol Number: 009531 Start Date*: 2016-03-11
    Sponsor Name:Queen Mary University of London
    Full Title: A randomised, blinded, placebo-controlled Phase 2a study to evaluate the safety and efficacy of Artesunate treatment in severely injured trauma patients with traumatic haemorrhage.
    Medical condition: Organ Dysfunction and Failure in Traumatic Hemorrhage
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-003023-38 Sponsor Protocol Number: GERMAIN Start Date*: 2013-10-30
    Sponsor Name:Friedrich-Schiller-Universität Jena
    Full Title: Phase II study of Bortezomib, Melphalan, Prednisone (VMP) followed by Lenalidomide maintenance vs. VMP without maintenance in Myeloma patients not eligible to high-dose chemotherapy and autologous ...
    Medical condition: multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-001100-38 Sponsor Protocol Number: FARM97AJNN Start Date*: 2014-07-09
    Sponsor Name:DIPART. DI NEUROSCIENZE, SCIENZE RIPRODUTTIVE E ODONTOSTOMATOLOGICHE DELL’UNIVERSITà DEGLI STUDI DI NAPOLI “FEDERICO II"
    Full Title: Antagonists of Angiotensin II Receptors in sepsis
    Medical condition: SEPSIS
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021881 - Infections and infestations 10040047 Sepsis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-002120-24 Sponsor Protocol Number: OP-104 Start Date*: 2017-12-14
    Sponsor Name:Oncopeptides AB
    Full Title: An Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and Dexamethasone in Combination with either Bortezomib or Daratumumab in Patients with Relapsed or Relapsed-Refractory Multip...
    Medical condition: Patients with Relapsed or Relapsed-Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004851 10028229 Multiple myelomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Prematurely Ended) PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-000654-22 Sponsor Protocol Number: 6998 Start Date*: 2018-11-09
    Sponsor Name:Hôpitaux Universitaires de Strasbourg
    Full Title: A Prospective, Randomized Multicenter, Double Blind Clinical Trial Comparing Inhaled Dornase Alfa and Its Placebo to Reduce the Incidence of Moderate to Severe ARDS in Ventilated Trauma Patients in...
    Medical condition: Multiple Trauma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-006782-83 Sponsor Protocol Number: EC08/00230 Start Date*: 2013-09-24
    Sponsor Name:Hospital Universitario Virgen de las Nieves
    Full Title: Prevention MODS by modulating the inflammatory response through melatonin administration in surgical patients with severe sepsis.
    Medical condition: Septic patients of abdominal surgery
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004810-25 Sponsor Protocol Number: 205678 Start Date*: 2018-07-19
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in Participants with Multiple Myeloma Who Had 3 or Mo...
    Medical condition: Relapsed/Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004689-93 Sponsor Protocol Number: 207497 Start Date*: 2019-04-29
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination with Lena...
    Medical condition: Relapsed / Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2006-002112-99 Sponsor Protocol Number: F1K-MC-EVDK Start Date*: 2006-09-26
    Sponsor Name:Eli Lilly & Company Limited
    Full Title: A Phase 2 Study to Evaluate Dose and Duration of Treatment of Drotrecogin Alfa (Activated) Using Serial Measurements of Protein C in Patients with Severe Sepsis and Multiple Organ Dysfunction
    Medical condition: severe sepsis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10040047 Sepsis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) SE (Prematurely Ended) FR (Completed) FI (Completed) IT (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-003993-29 Sponsor Protocol Number: 207503 Start Date*: 2020-05-12
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared with th...
    Medical condition: Relapsed/Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 00:47:38 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA